InVivo Therapeutics Holdings (NVIV) announced that University of California (UC), San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.
UC San Diego Medical Center, located in Hillcrest, has 390 beds and is one of only two Level I Trauma Centers in San Diego County. Joseph Ciacci, M.D., Clinical Professor of Surgery at the UC San Diego School of Medicine and Chief of Neurosurgery at the Veteran Affairs San Diego Healthcare System, has been named Principal Investigator at the site.
"My team and facility are well-suited for a clinical trial in this area. I look forward to being a part of this study," said Dr. Ciacci.
Mark Perrin, InVivo’s CEO and Chairman, said, "Dr. Ciacci and the team at the UC San Diego Medical Center serve as a valuable addition to our clinical network for The INSPIRE Study."
There are now 15 clinical sites participating in the clinical study:
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter.
The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
InVivo Therapeutics Holdings is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.